**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**
**(National Phase of International App.: PCT/US03/18202, WO 03/103604 A2)**

In re the
application of: **Gian Luca Araldi, *et al.***

International Application No.: **PCT/US03/18202**

International Filing Date: **June 9, 2003**

U.S. Serial No.: **Not Yet Assigned**

Filed: **Herewith**

For: **GAMMA LACTAMS AS PROSTAGLANDIN AGONISTS AND USE THEREOF**

Attorney Docket No.: **SNI-003US**

Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

"Express Mail" mailing label number EV 418604983 US

Date of Deposit
I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Mail Stop PCT Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450

Signature

Cynthia M. Soroos, Esq.
Please Print Name of Person Signing

## INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Applicants and their Attorney are aware of the following publications and information, listed on the attached PTO Form SB/08, and in accordance with 37 CFR §1.97 hereby submit these publications for the Examiner's consideration. Reference ID No. A10 was cited in an International Search Report mailed December 10, 2003 during the prosecution of PCT/US03/18202 which corresponds to the above referenced application. A copy of the report and each cited publication is enclosed. Furthermore, in accordance with

37 CFR §1.704(d), Applicants note that this communication was not received by any individual designated in §1.56(c) more than thirty days prior to the filing of this statement.

This statement is not to be interpreted as a representation that the cited publications are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any publication herein be construed *per se* as a representation that such publication is prior art. Moreover, Applicants understand that the Examiner will make an independent evaluation of the cited publications.

In accordance with 37 CFR §1.97(b)(1), no additional costs are believed to be due in connection with the filing of this Information Disclosure Statement. However, please charge any necessary fees in connection with the enclosed statement to our Deposit Order Account No. 12-0080.

Respectfully submitted,
LAHIVE & COCKFIELD, LLP



Cynthia M. Soroos, Esq.
Registration No. 53,623
Attorney for Applicants

28 State Street
Boston, MA 02109
(617) 227-7400

Date: 10 December 2004

GAD/DFS/CMS/les
Enclosures

PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE


Substitute for form 1449A/B/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(Use as many sheets as necessary)*

Sheet 1 of 2

| Complete if Known | |
|---|---|
| Application Number | Not Yet Assigned |
| Filing Date | Herewith |
| First Named Inventor | Gian Luca Araldi |
| Art Unit | N/A |
| Examiner Name | Not Yet Assigned |
| Attorney Docket Number | SNI-003US |

## U.S. PATENT DOCUMENTS

| Examiner Initials* | Cite No.[1] | Document Number Number-Kind Code[2] (if known) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|---|---|---|---|---|---|
| | A1 | 3,873,566 | 03-25-1975 | Scribner | |
| | A2 | 4,003,911 | 01-18-1977 | Scribner | |
| | A3 | 4,033,989 | 07-05-1977 | Bundy | |
| | A4 | 4,090,019 | 05-16-1978 | Williams, *et al.* | |
| | A5 | 4,211,876 | 07-08-1980 | Scribner | |
| | A6 | 5,605,814 | 02-25-1997 | Abramovitz, *et al.* | |
| | A7 | 5,759,789 | 06-02-1998 | Abramovitz, *et al.* | |
| | A8 | 6,211,197 B1 | 04-03-2001 | Belley, *et al.* | |
| | A9 | 6,288,120 B1 | 09-11-2001 | Cameron, *et al.* | |
| | A10 | US2002/0065308 A1 | 05-30-2002 | Cameron, *et al.* | |

## FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No.[1] | Foreign Patent Document Country Code[3]-Number[4]-Kind Code[5] (if known) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T[6] |
|---|---|---|---|---|---|---|
| | A11 | WO 96/03380 A1 | 02-08-1996 | Zeneca Limited | | |
| | A12 | WO 96/06822 A1 | 03-07-1996 | Zeneca Limited | | |
| | A13 | EP 0 752 421 A1 | 01-08-1997 | Zeneca Limited | | |
| | A14 | WO 97/00863 A1 | 01-09-1997 | Zeneca Limited | | |
| | A15 | WO 97/00864 A1 | 01-09-1997 | Zeneca Limited | | |
| | A16 | EP 1 110 949 A1 | 06-27-2001 | Pfizer Products Inc. | | |
| | A17 | WO 02/24647 A1 | 03-28-2002 | Ono Pharmaceutical Co., Ltd. | | |
| | A18 | WO 03/007941 A1 | 01-30-2003 | F.Hoffmann -La Roche AG | | |
| | A19 | WO 03/009872 A1 | 05-12 2004 | Ono Pharmaceutical Co., Ltd. | | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

## NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No.[1] | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T[2] |
|---|---|---|---|
| | A20 | Abramovitz, *et al.* "The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs." Biochim Biophys Acta. 2000 Jan 17;1483(2):285-93. | |
| | A21 | Bennett, *et al.* "Synthesis and biological activity of a series of 1-aryl-3-pyrazolidinones." J Med Chem. 1976 May;19(5):715-7. | |
| | A22 | Boie, *et al.* "Molecular cloning and characterization of the four rat prostaglandin $E_2$ prostanoid receptor subtypes." Eur J Pharmacol. 1997 Dec 11;340(2-3):227-41. | |
| | A23 | Coleman, *et al.* "Prostanoids and their receptors. Comprehensive Medicinal Chemistry." 1990 3:643-714. | |

| Examiner Signature | | Date Considered | |
|---|---|---|---|

PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

| Sheet | 2 | of | 2 |
|---|---|---|---|

| Complete if Known | |
|---|---|
| Application Number | Not Yet Assigned |
| Filing Date | Herewith |
| First Named Inventor | Gian Luca Araldi |
| Art Unit | N/A |
| Examiner Name | Not Yet Assigned |
| Attorney Docket Number | SNI-003US |

## NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No.[1] | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T[2] |
|---|---|---|---|
| | B1 | Coleman, *et al.* " International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes." Pharmacol Rev. 1994 Jun;46(2):205-29. | |
| | B2 | Corey, *et al.* "A stable and easily prepared catalyst for the enantioselective reduction of ketones. Applications to Multistep Systheses." J. Am. Chem. Soc. 1987. 109:7925-26. | |
| | B3 | Fleisch, *et al.* "LY171883, 1-< 2-hydroxy-3-propyl-4-< 4-(1H-tetrazol-5-yl) butoxy > phenyl > ethanone, an orally active leukotriene D4 antagonist." J Pharmacol Exp Ther. 1985 Apr;233(1):148-57. | |
| | B4 | Gardiner, PJ. "Characterization of prostanoid relaxant/inhibitory receptors (psi) using a highly selective agonist, TR4979." Br J Pharmacol. 1986 Jan;87(1):45-56. | |
| | B5 | Hundertmark, *et al.* "$Pd(PhCN)_{(2)}Cl_{(2)}/P(t\text{-}Bu)_{(3)}$: a versatile catalyst for Sonogashira reactions of aryl bromides at room temperature." Org Lett. 2000 Jun 15;2(12):1729-31. | |
| | B6 | Ichikawa, *et al.* "Molecular aspects of the structures and functions of the prostaglandin E receptors." J Lipid Mediat Cell Signal. 1996 Sep;14(1-3):83-7. | |
| | B7 | Langlois, *et al.* "Intramolecular Mitsunobu reaction in the region- and stereoselective synthesis of cis-4,5-disubstituted piperidin-2-ones." Tetrahedron Letters. 2000 41:8285-8288. | |
| | B8 | Macdonald, *et al.* "Syntheses of trans-5-oxo-hexahydro-pyrrolo[3,2-b]pyrroles and trans-5-oxo-hexahydro-furo[3,2-b]pyrroles (pyrrolidine trans-lactams and trans-lactones): new pharmacophores for elastase inhibition." J Med Chem. 1998 Oct 8;41(21):3919-22. | |
| | B9 | Mikolajczyk, *et al.* "Synthesi8s of (±)-Rosaprostol." J. Org. Chem. 1998. 63:8894-8897. | |
| | B10 | Minami, *et al.* "Characterization of EP-receptor subtypes involved in allodynia and hyperalgesia induced by intrathecal administration of prostaglandin E2 to mice." Br J Pharmacol. 1994 Jul;112(3):735-40. | |
| | B11 | Nair, *et al.* "Folate analogues. 31. Synthesis of the reduced derivatives of 11-deazahomofolic acid, 10-methyl-11-deazahomofolic acid, and their evaluation as inhibitors of glycinamide ribonucleotide formyltransferase." J Med Chem. 1989 Jun;32(6):1277-83. | |
| | B12 | Okuma, *et al.* "An Efficient Synthesis of (R)-(+)-Recifeiolide and Related Macrolides by Using Enantiomerically Pure (R)- (-)-5-Methyl-2,2,2-triphenyl-1,2$A^{5}$-oxaphospholane." Tetrahedron. 1998. 54:4243-50. | |
| | B13 | Tani, *et al.* "Synthesis of a Highly Selective EP2-Receptor Agonist." Synlett. 2002, pp. 239-242. | |
| | B14 | Thivierge, *et al.* "Prostaglandin E2 induces resistance to human immunodeficiency virus-1 infection in monocyte-derived macrophages: downregulation of CCR5 expression by cyclic adenosine monophosphate." Blood. 1998 Jul 1;92(1):40-5. | |
| | B15 | Ushikubi, *et al.* "Roles of prostanoids revealed from studies using mice lacking specific prostanoid receptors." Jpn J Pharmacol. 2000 Aug;83(4):279-85. | |
| | B16 | Wilkinson, *et al.* "Diethylanilineborane: A Practical, safe, and consistent-quality borane source for the large-scale enantioselective reduction of a ketone intermediate in the synthesis of (R,R)-Formoterol." Organic Process Research & Development. 2002 6:146-8. | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1]Applicant's unique citation designation number (optional). [2]Applicant is to place a check mark here if English language Translation is attached.

| Examiner Signature | | Date Considered | |
|---|---|---|---|